Detalhe da pesquisa
1.
Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.
Oncologist
; 2024 May 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38815152
2.
T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer.
Future Oncol
; 2022 Jul 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35852104
3.
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.
N Engl J Med
; 373(3): 232-42, 2015 Jul 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-26052984
4.
A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Cardiovasc Diabetol
; 16(1): 112, 2017 09 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28893244
5.
Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
Diabetes Obes Metab
; 19(11): 1587-1593, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28432745
6.
Randomized clinical trial comparing the efficacy and safety of treatment with the once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor omarigliptin or the once-daily DPP-4 inhibitor sitagliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Diabetes Obes Metab
; 19(3): 394-400, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28093853
7.
A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin.
BMC Endocr Disord
; 17(1): 70, 2017 Nov 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29110647
8.
A randomised, double-blind, trial of the safety and efficacy of omarigliptin (a once-weekly DPP-4 inhibitor) in subjects with type 2 diabetes and renal impairment.
Int J Clin Pract
; 71(6)2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28449320
9.
Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181.
J Clin Oncol
; 40(4): 382-391, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34730989
10.
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Cell Metab
; 4(4): 275-82, 2006 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17011500
11.
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer.
J Clin Oncol
; 38(35): 4138-4148, 2020 12 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33026938
12.
One-year health-related quality of life outcomes in weight loss trial participants: comparison of three measures.
Health Qual Life Outcomes
; 7: 53, 2009 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-19505338
13.
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes.
Diabetes Res Clin Pract
; 138: 253-261, 2018 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-29079379
14.
Use of Prohibited Medication, a Potentially Overlooked Confounder in Clinical Trials: Omarigliptin (Once-weekly DPP-4 Inhibitor) Monotherapy Trial in 18- to 45-year-olds.
Clin Ther
; 39(10): 2024-2037, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28923291
15.
A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Curr Med Res Opin
; 33(10): 1853-1860, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28547998
16.
A randomized, double-blind, non-inferiority trial evaluating the efficacy and safety of omarigliptin, a once-weekly DPP-4 inhibitor, or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Curr Med Res Opin
; 33(10): 1861-1868, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28548024
17.
Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Diabetes Care
; 40(4): 494-501, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-28057693
18.
Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes.
Diabetes Care
; 38(11): 2106-14, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26310692
19.
Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
J Bone Miner Res
; 19(8): 1259-69, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15231012
20.
Alendronate reduces the risk of multiple symptomatic fractures: results from the fracture intervention trial.
J Am Geriatr Soc
; 50(3): 409-15, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11943033